Effect of rituximab on long-term damage acquisition in patients with systemic lupus erythematosus
As an effective B-cell depleting therapy, rituximab is a valid therapeutic option for SLE patients, especially in those with refractory or life-threatening manifestations. While patients treated with rituximab initially had higher damage, their rate of damage progression was slower compared with those receiving standard therapies.
Authors
- Teresa Moitinho de Almeida
- David Isenberg (ORCID: https://orcid.org/0000-0001-9514-2455)
- Anderson Brito (ORCID: https://orcid.org/0000-0001-8646-5578)
- Sofia Miranda (ORCID: https://orcid.org/0000-0002-5591-5641)
Institutions
- Hospital de Egas Moniz (PT)
- Instituto de Medicina Integral Professor Fernando Figueira (BR)
- Hospital do Divino Espírito Santo (PT)
- University College London (GB)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1093/rheumatology/keaf248
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.67